scholarly journals Recurrence of Aggressive Urothelial Carcinoma in an Ileal Neobladder without Involvement of Remaining Urothelium

2021 ◽  
Vol 2 (2) ◽  
pp. 70-72
Author(s):  
Amanda M
Keyword(s):  
Urothelial Carcinoma ◽  
Carcinoma In Situ ◽  
Upper Urinary Tract ◽  
Emission Tomography ◽  
Bacillus Calmette Guerin ◽  
Ileal Neobladder ◽  
Radical Cystoprostatectomy ◽  
Positron Emission ◽  
Cancer Network

We review a case of a 70-year-old male with a recurrence of urothelial carcinoma in an ileal neobladder without involvement of the remaining urothelium two years after a radical cystoprostatectomy. This case is extremely rare especially due to the lack of recurrence in the urethra or upper urinary tract. Abbreviations BCG: Bacillus Calmette-Guérin; CIS: Carcinoma in situ; CT: Computerized/computed tomography; NCCN: National Comprehensive Cancer Network; PE: Pulmonary embolism; PET: Positron emission tomography; RC: Radical cystectomy; TURBT: Trans-urethral resection of bladder tumor; UC: Urothelial carcinoma. Keywords: Urothelial carcinoma; Ileal; neobladder; Tumor; Recurrence; Metastasis.

LONG-TERM EFFECTS OF BACILLUS CALMETTE-GUERIN PERFUSION THERAPY FOR UPPER URINARY TRACT UROTHELIAL CARCINOMA IN SITU

2008 ◽  
Vol 179 (4S) ◽  
pp. 120-120
Author(s):  
Takahiro Yoneyama ◽  
Hayato Yamamoto ◽  
Akiko Okamoto ◽  
Atsushi Imai ◽  
Ikuya Iwabuchi ◽  
...  
Keyword(s):  
Urinary Tract ◽  
Urothelial Carcinoma ◽  
Carcinoma In Situ ◽  
Upper Urinary Tract ◽  
Bacillus Calmette Guerin ◽  
Long Term Effects ◽  
Urinary Tract Urothelial Carcinoma

Clinical outcome of bacillus Calmette-Guerin perfusion therapy for carcinoma in situ of the upper urinary tract

2002 ◽  
Vol 9 (12) ◽  
pp. 677-680 ◽  
Author(s):  
HIDEAKI MIYAKE ◽  
HIROSHI ETO ◽  
SHOJI HARA ◽  
HIROSHI OKADA ◽  
SADAO KAMIDONO ◽  
...  
Keyword(s):  
Urinary Tract ◽  
Clinical Outcome ◽  
Carcinoma In Situ ◽  
Upper Urinary Tract ◽  
Bacillus Calmette Guerin

Urothelial Carcinoma In Situ and Treatment of Bacillus Calmette-Guérin Failures

2019 ◽  
pp. 337-349
Author(s):  
David D’Andrea ◽  
Fred Witjes ◽  
Francesco Soria ◽  
Shahrokh F. Shariat
Keyword(s):  
Urothelial Carcinoma ◽  
Carcinoma In Situ ◽  
Bacillus Calmette Guerin

The efficacy of Bacillus Calmette-Guerin instillation therapy of the upper urinary tract for carcinoma in situ

1999 ◽  
Vol 4 (5) ◽  
pp. 295-297
Author(s):  
T. Hattori ◽  
G. Kimura ◽  
K. Horiuchi ◽  
N. Tsuboi ◽  
K. Yoshida ◽  
...  
Keyword(s):  
Urinary Tract ◽  
Carcinoma In Situ ◽  
Upper Urinary Tract ◽  
Bacillus Calmette Guerin ◽  
Instillation Therapy

Long-term outcome of bacilles Calmette-Guerin perfusion therapy for upper urinary tract urothelial carcinoma in situ.

2013 ◽  
Vol 31 (6_suppl) ◽  
pp. 265-265
Author(s):  
Takahiro Yoneyama ◽  
Naoki Sugiyama ◽  
Yuuichirou Suzuki ◽  
Akiko Okamoto ◽  
Hayato Yamamoto ◽  
...  
Keyword(s):  
Urinary Tract ◽  
Side Effects ◽  
Urothelial Carcinoma ◽  
Carcinoma In Situ ◽  
Upper Urinary Tract ◽  
Term Outcome ◽  
Long Term Outcome ◽  
Urinary Tract Urothelial Carcinoma

265 Background: Bacillus Calmette-Guerin (BCG) therapy has already been established as a treatment for muscle noninvasive bladder cancer. Although there are several reports indicating the effectiveness of BCG perfusion therapy for the upper urinary tract urothelial carcinoma in situ (CIS), it is not well established yet. We conducted a retrospective study to assess the long-term outcome of BCG perfusion therapy for the upper urinary tract CIS. Methods: Twenty-six subjects (20 male, 6 female) who received BCG perfusion therapy for the upper urinary tract CIS from December 1997 to December 2011 were enrolled. Ten subjects had the entire urinary tract CIS, seven had bilateral, nine had unilateral CIS of the urinary tract. The average period of observation was 52.6 months (ranging from 5 to 156 months), and the average subject age was 73.6 years (ranging from 56 to 90 years). We used a double-J catheter for 17 cases, a transvesical single-J catheter whose curl was positions in an upper calyx for eight cases, and a straight ureteral catheter inserted for ureterocutaneostomy for one case. We used 80 mg of BCG for the first five cases, 40 mg for the late twenty-one cases. Urine cytology was performed to assess the treatment validity. Results: Of the 26 cases, the treatment protocol was completed in 21 cases. Urine cytology tests became negative in 22 of the 26 subjects (84.6%) who underwent upper urinary tract perfusion. Among these 22 subjects who had negative tests, five subjects had a recurrence in their upper urinary tracts. Side effects were observed in 25 subjects (96.5%), and the most common side effect was bladder irritation. Localized renal tuberculosis which was successfully treated with conservative therapy was seen in two cases. Conclusions: BCG perfusion therapy for the upper urinary tract CIS is active. However, severe side effects are possible, and careful observation is essential while using this therapy.

Sign in / Sign up

Export Citation Format

Share Document